Alzheimer's disease is a progressive neurodegenerative disease that slowly destroys memory and cognitive skills. It is the most common cause of dementia among older people. Global Alzheimer's drugs market growth is driven by rising prevalence of Alzheimer's disease worldwide. According to WHO, around 50 million people globally have dementia with nearly 10 million new cases every year. Rising approval and launch of novel disease modifying drugs that target the underlying pathophysiology of Alzheimer's can drive the market growth over the forecast period.
Global Alzheimer's drugs market growth is driven by rising geriatric population, increasing prevalence of Alzheimer's disease, introduction of novel disease modifying drugs, growing healthcare expenditure and rising awareness about the condition. However, high costs associated with drug R&D and failure of late stage clinical trials can hamper the market growth. Developing regions with large elderly populations an offer significant growth opportunities. Technological advancements in early diagnosis and advancements in understanding the disease pathology can also offer new opportunities.
- This report provides in-depth analysis of the global Alzheimer's drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Alzheimer's drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global Alzheimer's drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alzheimer's drugs market.
-
- Cholinesterase Inhibitors
- Donepezil
- Rivastigmine
- Galantamine
- NMDA Receptor Antagonist
- Combination Therapy
- Pipeline Drugs
- Aducanumab
- Lecanemab
- Donanemab
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- AbbVie, Inc.
- Teva Pharmaceuticals Ltd.
- Eisai Co., Ltd.
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Novartis AG
- Zydus Lifesciences Ltd (CADILA)
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma Ltd.
- Amneal Pharmaceuticals Inc.
- Macleods Pharmaceuticals Ltd.
- Viatris Inc.
- Lupin Ltd.
- Cipla Ltd.
- Torrent Pharmaceuticals Ltd.
- Unichem laboratories ltd
- Lannett Inc.
